RS57406B1 - Derivat 4-alkinil imidazola i lekovi koji ga sadrže kao aktivni sastojak - Google Patents

Derivat 4-alkinil imidazola i lekovi koji ga sadrže kao aktivni sastojak

Info

Publication number
RS57406B1
RS57406B1 RS20180743A RSP20180743A RS57406B1 RS 57406 B1 RS57406 B1 RS 57406B1 RS 20180743 A RS20180743 A RS 20180743A RS P20180743 A RSP20180743 A RS P20180743A RS 57406 B1 RS57406 B1 RS 57406B1
Authority
RS
Serbia
Prior art keywords
group
compound
mmol
methyl
general formula
Prior art date
Application number
RS20180743A
Other languages
English (en)
Serbian (sr)
Inventor
Satoru Ikegami
Atsushi Watanabe
Kimio Hirano
Tadashi Ohyama
Original Assignee
Kaken Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharmaceutical Co Ltd filed Critical Kaken Pharmaceutical Co Ltd
Publication of RS57406B1 publication Critical patent/RS57406B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RS20180743A 2013-06-12 2014-06-12 Derivat 4-alkinil imidazola i lekovi koji ga sadrže kao aktivni sastojak RS57406B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013123968 2013-06-12
EP14811154.5A EP3009426B1 (en) 2013-06-12 2014-06-12 4-alkynyl imidazole derivative and medicine comprising same as active ingredient
PCT/JP2014/065643 WO2014200075A1 (ja) 2013-06-12 2014-06-12 4-アルキニルイミダゾール誘導体およびそれを有効成分として含有する医薬

Publications (1)

Publication Number Publication Date
RS57406B1 true RS57406B1 (sr) 2018-09-28

Family

ID=52022361

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20180743A RS57406B1 (sr) 2013-06-12 2014-06-12 Derivat 4-alkinil imidazola i lekovi koji ga sadrže kao aktivni sastojak

Country Status (28)

Country Link
US (2) US9593081B2 (enExample)
EP (1) EP3009426B1 (enExample)
JP (1) JP6276760B2 (enExample)
KR (1) KR102212981B1 (enExample)
CN (1) CN105431416B (enExample)
AU (1) AU2014279113B2 (enExample)
BR (1) BR112015030315B1 (enExample)
CA (1) CA2914997C (enExample)
DK (1) DK3009426T3 (enExample)
ES (1) ES2669977T3 (enExample)
HR (1) HRP20180703T1 (enExample)
HU (1) HUE039015T2 (enExample)
IL (1) IL242912A0 (enExample)
LT (1) LT3009426T (enExample)
MX (1) MX369804B (enExample)
MY (1) MY168609A (enExample)
NO (1) NO3009426T3 (enExample)
NZ (1) NZ715837A (enExample)
PH (1) PH12015502745B1 (enExample)
PL (1) PL3009426T3 (enExample)
PT (1) PT3009426T (enExample)
RS (1) RS57406B1 (enExample)
RU (1) RU2662806C2 (enExample)
SG (1) SG11201510121RA (enExample)
SI (1) SI3009426T1 (enExample)
TR (1) TR201807659T4 (enExample)
WO (1) WO2014200075A1 (enExample)
ZA (1) ZA201600135B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO3009426T3 (enExample) * 2013-06-12 2018-09-29
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
EP3541801A4 (en) * 2016-11-18 2020-04-29 Dow AgroSciences LLC 4- (6- (2- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H
ES2887041T3 (es) 2017-05-18 2021-12-21 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de PGE2
EP3625223B1 (en) 2017-05-18 2021-08-11 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
ES2893452T3 (es) 2017-05-18 2022-02-09 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de PGE2
AR111807A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2
DK3625224T3 (da) 2017-05-18 2021-11-08 Idorsia Pharmaceuticals Ltd N-substituerede indolderivater
US11479550B2 (en) 2017-05-22 2022-10-25 Ono Pharmaceutical Co., Ltd. EP4 antagonist
JP2020142989A (ja) * 2017-06-21 2020-09-10 Meiji Seikaファルマ株式会社 イミダゾール誘導体及びそれを含有する医薬
CN117643587A (zh) * 2018-02-05 2024-03-05 深圳市原力生命科学有限公司 用于治疗癌症的杂二环羧酸
CN108997252B (zh) * 2018-07-27 2020-04-28 常州大学 一种恶二唑衍生物的绿色合成方法
US20230390303A1 (en) 2020-11-13 2023-12-07 Ono Pharmaceutical Co., Ltd. Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030072614A (ko) * 2001-01-31 2003-09-15 화이자 프로덕츠 인크. Pde4 이소자임 억제제로 유용한 티아졸릴-,옥사졸릴-, 피롤릴- 및 이미다졸릴-산 아미드 유도체
WO2003016254A1 (en) 2001-08-09 2003-02-27 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
EP1506220A1 (en) 2002-05-23 2005-02-16 Theratechnologies Inc. Antagonistic peptides of prostaglandin e2 receptor subtype ep4
KR100747401B1 (ko) 2003-09-03 2007-08-08 화이자 인코포레이티드 프로스타글란딘 e2 길항제로서의 페닐 또는 피리딜 아미드 화합물
WO2005105733A1 (en) 2004-05-04 2005-11-10 Pfizer Japan Inc. Ortho substituted aryl or heteroaryl amide compounds
WO2005105732A1 (en) 2004-05-04 2005-11-10 Pfizer Japan Inc. Substituted methyl aryl or heteroaryl amide compounds
AU2006215567B2 (en) * 2005-02-16 2011-05-12 Abbott Healthcare Products B.V. 1H-imidazole derivatives as cannabinoid CB2 receptor modulators
ES2392192T3 (es) 2006-04-24 2012-12-05 Merck Canada Inc. Derivados de indol amida como antagonistas del receptor EP4
JP5183628B2 (ja) 2006-06-12 2013-04-17 メルク カナダ インコーポレイテッド Ep4受容体リガンドとしてのインドリンアミド誘導体
JP5259592B2 (ja) 2006-08-11 2013-08-07 メルク カナダ インコーポレイテッド Ep4受容体リガンドとしてのチオフェンカルボキサミド誘導体
AU2008221194B2 (en) * 2007-02-26 2013-06-27 Merck Canada Inc. Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists
AU2008270438B2 (en) * 2007-07-02 2013-10-10 F. Hoffmann-La Roche Ag Imidazole derivatives as CCR2 receptor antagonists
WO2009005076A1 (ja) 2007-07-03 2009-01-08 Astellas Pharma Inc. アミド化合物
BRPI0912778B1 (pt) 2008-05-14 2019-04-30 Astellas Pharma Inc. Composto de amida, composição farmacêutica compreendedo dito composto e uso do mesmo para o tratamento de insuficiência renal crônica ou nefropatia diabética
WO2010019796A1 (en) 2008-08-14 2010-02-18 Chemietek, Llc Heterocyclic amide derivatives as ep4 receptor antagonists
CN103097358B (zh) 2010-09-21 2015-04-08 卫材R&D管理有限公司 药物组合物
CA2820109C (en) 2010-12-10 2018-01-09 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
WO2012103071A2 (en) 2011-01-25 2012-08-02 Eisai R&D Management Co., Ltd. Compounds and compositions
KR101760164B1 (ko) 2011-07-04 2017-07-20 로타팜 바이오테크 에스.알.엘 Ep4 수용체 길항제로서 사이클릭 아민 유도체
NO3009426T3 (enExample) * 2013-06-12 2018-09-29

Also Published As

Publication number Publication date
EP3009426A4 (en) 2016-10-19
US9593081B2 (en) 2017-03-14
HRP20180703T1 (hr) 2018-06-15
CN105431416A (zh) 2016-03-23
US9855257B2 (en) 2018-01-02
PL3009426T3 (pl) 2018-09-28
AU2014279113B2 (en) 2018-04-12
PH12015502745A1 (en) 2016-03-14
CA2914997C (en) 2021-07-20
RU2662806C2 (ru) 2018-07-31
CN105431416B (zh) 2019-01-08
DK3009426T3 (en) 2018-05-28
NZ715837A (en) 2020-01-31
SI3009426T1 (en) 2018-06-29
JPWO2014200075A1 (ja) 2017-02-23
AU2014279113A1 (en) 2016-01-21
US20160130232A1 (en) 2016-05-12
ES2669977T3 (es) 2018-05-29
KR102212981B1 (ko) 2021-02-04
IL242912A0 (en) 2016-02-01
NO3009426T3 (enExample) 2018-09-29
CA2914997A1 (en) 2014-12-18
MX369804B (es) 2019-11-21
JP6276760B2 (ja) 2018-02-07
EP3009426A1 (en) 2016-04-20
HK1221215A1 (zh) 2017-05-26
BR112015030315B1 (pt) 2022-10-04
ZA201600135B (en) 2017-04-26
LT3009426T (lt) 2018-07-25
US20170128431A1 (en) 2017-05-11
BR112015030315A2 (pt) 2017-07-25
MY168609A (en) 2018-11-14
EP3009426B1 (en) 2018-05-02
RU2015155585A (ru) 2017-07-17
WO2014200075A1 (ja) 2014-12-18
PH12015502745B1 (en) 2019-01-25
MX2015017161A (es) 2016-04-06
TR201807659T4 (tr) 2018-06-21
PT3009426T (pt) 2018-06-08
HUE039015T2 (hu) 2018-12-28
KR20160018745A (ko) 2016-02-17
SG11201510121RA (en) 2016-01-28

Similar Documents

Publication Publication Date Title
RS57406B1 (sr) Derivat 4-alkinil imidazola i lekovi koji ga sadrže kao aktivni sastojak
JP6918819B2 (ja) オルトミクソウイルス感染の処置に有用な三環式化合物
TW200843744A (en) Dual-acting antihypertensive agents
WO2006074445A2 (en) Novel heteropyrrole analogs acting on cannabiniod receptors
RS57090B1 (sr) Derivat piridina
CN104822680A (zh) 咪唑并吡啶化合物
TW200524605A (en) Therapeutic agents
EP2520566A1 (en) New Pharmaceutical Compounds
CN108430974A (zh) RORγ调节剂
KR20100122512A (ko) 질소 함유 이환성 복소환 화합물
AU2012229859C1 (en) Nitrogen-containing saturated heterocyclic compound
JP2024534111A (ja) 芳香環系を含有する生物アンタゴニスト、その製造方法及び応用
JP5881837B2 (ja) テトラゾール化合物の脱保護方法
TW201245187A (en) Pyrazole derivatives
JP2023552655A (ja) ボロン酸化合物
JP2008539181A (ja) Ep1受容体アンタゴニストとして有用なフラン化合物
HK1221215B (zh) 4-炔基咪唑衍生物和含有其作为有效成分的药物
EP4522604A1 (en) Inhibitors of human respiratory syncytial virus and metapneumovirus
EA049406B1 (ru) Ингибиторы tead
JPWO2010113952A1 (ja) ムスカリン受容体拮抗薬